 UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical stage immuno-oncology company focused on developing its proprietary GammabodyTM platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24th Annual Global Investment Conference being held virtually and in New York City. 